Prelude Therapeutics INC 10-Q quarterly reports

Prelude Therapeutics Incorporated announced its financial results for the second quarter ended June 30, 2026, highlighting progress in its oncology pipeline and a significant capital raise.

Prelude Therapeutics Inc. reported its first-quarter 2026 financial results, highlighting progress in its oncology pipeline and a significant cash position following a recent offering.

Prelude Therapeutics reported a reduced net loss for Q3 2025, secured $60 million in new capital from Incyte, and strategically paused its SMARCA2 degrader program to focus on JAK2 and KAT6A, while acknowledging substantial doubt about its going concern ability.

Prelude Therapeutics reported continued operating losses and a going concern warning, alongside progress in its oncology pipeline and a Nasdaq minimum bid price deficiency.

Prelude Therapeutics reports a net loss of $32.1 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Prelude Therapeutics reported a net loss of $32.3 million for the third quarter of 2024, while highlighting progress in its clinical programs and a new licensing agreement.

Prelude Therapeutics reported a net loss of $66.2 million for the first six months of 2024, while advancing its clinical programs and securing a new licensing agreement.

Prelude Therapeutics reported a net loss of $31.4 million for the first quarter of 2024, while continuing to advance its clinical programs.